Hypothesis

Recurrent pregnancy loss (RPL) in antiphospholipid syndrome (APS) involves a non-thrombotic, complement C5a-driven ferroptotic death pathway in placental trophoblasts that operates independently of the canonical thrombotic microangiopathy model and is detectable via serum lipid peroxidation biomarkers 4–8 weeks before fetal demise.

Background

The prevailing model attributes APS-related RPL primarily to placental thrombosis triggered by antiphospholipid antibodies (aPL) binding β2-glycoprotein I on trophoblast membranes, activating complement and coagulation cascades. However, anticoagulation alone fails to prevent RPL in 20–30% of obstetric APS cases, suggesting non-thrombotic mechanisms contribute substantially. Recent work has shown that: (1) complement C5a generated at the feto-maternal interface activates C5aR1 on trophoblasts, inducing reactive oxygen species (ROS) independent of neutrophil recruitment; (2) ferroptosis — iron-dependent, lipid peroxidation-mediated cell death — is emerging as a key pathway in placental dysfunction; and (3) aPL-bound trophoblasts upregulate transferrin receptor 1 (TfR1) and downregulate GPX4, the master ferroptosis suppressor.

Proposed Mechanism

aPL–β2GPI complexes on syncytiotrophoblast surfaces activate the classical complement pathway through C1q binding. Local C5a generation signals through trophoblast C5aR1, triggering: (a) NADPH oxidase 4 (NOX4) upregulation, increasing mitochondrial and cytoplasmic ROS; (b) labile iron pool expansion via hepcidin-independent TfR1 upregulation and ferritin degradation through NCOA4-mediated ferritinophagy; (c) GPX4 transcriptional suppression via NF-κB-mediated p53 stabilization. The convergence of iron overload, lipid ROS, and GPX4 insufficiency triggers ferroptotic trophoblast death, releasing damage-associated molecular patterns (DAMPs) including HMGB1 and oxidized phospholipids that amplify local inflammation and impair placentation.

Testable Predictions

1. Serum 4-HNE and MDA levels (lipid peroxidation markers) will be significantly elevated at 8–12 weeks gestation in APS pregnancies destined for RPL versus successful pregnancies, with AUC >0.80 at 4–8 weeks before fetal loss.
2. Placental tissue from APS-RPL will show ferroptosis signatures (accumulated lipid ROS, depleted GPX4, elevated TfR1, shrunken mitochondria on EM) predominantly in syncytiotrophoblast, co-localizing with C5a receptor expression but NOT with fibrin deposition.
3. C5a receptor antagonism (e.g., avacopan) in murine APS models will reduce trophoblast death and improve live birth rates even without anticoagulation, while ferroptosis inhibitors (ferrostatin-1, liproxstatin-1) will show equivalent or superior protection.
4. GPX4 conditional knockout in murine trophoblasts will phenocopy APS-RPL without requiring aPL or complement activation.

Limitations

• Murine placentation differs structurally from human (hemochorial vs. hemotrichorial), limiting translational inference.
• Serum lipid peroxidation markers lack organ specificity — elevated 4-HNE could reflect maternal hepatic or systemic oxidative stress.
• The relative contribution of ferroptosis versus apoptosis and necroptosis in trophoblast death remains to be quantified; these pathways likely co-exist.
• C5a-driven ferroptosis may represent a subset mechanism operating primarily in non-thrombotic APS phenotypes rather than a universal pathway.

Clinical Significance

If validated, this hypothesis reframes obstetric APS pathogenesis beyond thrombosis, explaining anticoagulation-refractory RPL and opening therapeutic avenues through complement inhibition (eculizumab, avacopan) and ferroptosis suppression (vitamin E, selenium supplementation, investigational GPX4 activators). Early serum ferroptosis biomarkers could stratify pregnant APS patients into thrombotic vs. ferroptotic phenotypes, enabling targeted prevention. This represents a paradigm shift from blanket anticoagulation toward mechanism-specific therapy in obstetric APS.

LES AI • DeSci Rheumatology